MDS Clinical Trials 2024

MDS Clinical Trials 2024

MDS research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in myelodysplastic syndromes clinical trials today.

Trials for MDS Patients

Trials for Myelomonocytic Leukemia Patients

Trials for HLA-A Positive Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to mds

What are the top hospitals conducting mds research?

When it comes to cutting-edge clinical trials in the field of myelodysplastic syndromes (MDS), several top hospitals are making significant strides. In Boston, the Dana Farber Cancer Institute leads the way with an impressive 13 active MDS trials and a commendable history of 42 completed studies since their first recorded trial in 2001. Another institution contributing to advancements in MDS research is Massachusetts General Hospital, also located in Boston. They currently have seven ongoing MDS trials and have conducted a remarkable total of 47 trials dating back to their earliest recorded trial in 1984.

Moving southwards to Miami, we find the University of Miami playing an important role by conducting seven active clinical trials for MDS while accumulating experience from sixteen previously held investigations since initiating their first trial on this condition just fifteen years ago, in 2006.

Meanwhile, Washington University School of Medicine takes center stage as one of the leading institutions researching MDS. With six current clinical trials focused on this condition and a robust track record consisting of forty-one completed studies since they started recording data for these types of cases around eighteen years ago(way back till2003).

Finally rounding out our list is Fred Hutchinson Cancer Research Center situated amidst Seattle's vibrant medical community; despite a smaller number compared to other establishments mentioned so far still undeniably contribute significantly towards understanding Myelodysplastic Syndromes better.With six ongoing clinical tests under its belt combined with eighty-five previous experiments spanning three decades(making them one among most experienced) marking pivotal starting point exactly thirty years ago during1991

These esteemed hospitals represent beacons of hope for those affected by MDS worldwide. Through groundbreaking research and innovative approaches, each step taken brings us closer to more effective treatments and improved outcomes for patients living with this complex blood disorder.

Which are the best cities for mds clinical trials?

When it comes to MDS (myelodysplastic syndromes) clinical trials, several cities emerge as leading hubs for research and innovation. Among them are Boston, Massachusetts, with 36 active trials investigating treatments like H3B-8800 (RVT-2001), Venetoclax, and Inqovi. Houston, Texas follows closely behind with 27 ongoing studies exploring therapies such as BGB-11417 and CC-95251. New york, New York is also a prominent city for MDS clinical trials with 20 active studies focusing on interventions like Bone Marrow Hematopoietic Stem Cell Transplantation and Oral Azacitidine. These cities offer individuals battling MDS the opportunity to participate in cutting-edge trials that may pave the way for improved treatment options and better outcomes.

Which are the top treatments for mds being explored in clinical trials?

Exciting advancements are taking place in the realm of MDS treatment, with several leading contenders emerging from ongoing clinical trials. One such contender is CPX-351, currently being explored in two active trials for MDS. Since its introduction in 2009, it has been involved in a total of 11 trials aiming to combat this condition. Another promising option on the horizon is luspatercept, which also boasts two active trials and has participated in a total of 15 MDS studies since its listing in 2016. Additionally, MBG453 and Atorvastatin show great potential as they both are engaged in two ongoing MDS trials each. As researchers delve deeper into these treatments' effectiveness and safety profiles, hope continues to grow for patients battling MDS worldwide

What are the most recent clinical trials for mds?

Recent clinical trials for MDS offer promising prospects in the field of hematologic disorders. Sitagliptin, Bortezomib, and Cyclophosphamide have demonstrated potential as a combined therapy for MDS patients. Another trial explores CD34+ Peripheral Blood Progenitor Cell Transplantation using Busulfan/Melphalan/Fludarabine regimen to improve outcomes in MDS cases. Itacitinib is also being investigated as a potential treatment option for this condition. Additionally, the use of Cy/Flu/TBI along with post-transplant CY shows promise in addressing MDS-related challenges. These ongoing trials shed light on new possibilities that may enhance the lives of individuals affected by MDS.

What mds clinical trials were recently completed?

In recent years, several clinical trials exploring potential treatments for MDS (myelodysplastic syndromes) have concluded, showcasing advancements in this field. Noteworthy completed trials include the investigation of Lemzoparlimab by AbbVie in June 2021, the evaluation of sabatolimab by Novartis Pharmaceuticals in May 2021, and a study on Azacitidine sponsored by Pfizer that also concluded in May 2021. These milestones highlight the ongoing efforts to find effective therapies for MDS and provide hope for patients affected by this condition.